Table 2.
Characteristics and outcomes of infection episodes.
| Characteristic | Detail (n = 111) |
|---|---|
| Treatment course | |
| BsAb cycles at time of infection (median, IQR) | 2 (1–7) |
| Cumulative prednisone-equivalent dose, 30 days (mg; median, IQR) | 266.7 (106.7–266.7) |
| Lowest neutrophil level, 14 days prior (x109/L; median, IQR) | 1.8 (1.1–2.3) |
| Lowest lymphocyte count, 14 days prior (x109/L; median, IQR) | 0.3 (0.1–0.7) |
| Prophylaxis (n, %) | |
| Antiviral |
Valaciclovir: 104 (94) Valganciclovir: 3 (3) Famciclovir: 3 (3) None: 1 (1) |
| Antifungal |
Fluconazole: 9 (8) Mould-active antifungal: 29 (26) Posaconazole: 24 (22) Voriconazole: 5 (5) None: 73 (66) |
| P. jirovecii prophylaxis |
Trimethoprim/Sulfamethoxazole: 104 (94) Dapsone: 5 (5) None: 2 (2) |
| Infection details | |
| Number of patients (n, %) | 35 (90) |
| Grade of infection |
1: 37 (33) 2: 50 (45) 3: 22 (20) 4: 0 (0) 5: 2 (2) |
| Infection category! |
MDI: 33 (30) CDI: 43 (39) FUF: 35 (32) |
| Site of infection |
Respiratory: 46 (41) Urinary: 4 (4) Bloodstream: 6 (5) Skin and soft tissue: 4 (4) Gastrointestinal tract: 8 (7) Ear nose and throat: 6 (5) Genital: 2 (2) CRS: 31 (28) Unknown: 4 (4) |
| Pathogen details (n, %) | |
| Pathogens isolateda |
Bacterial: 15 (39) Gram Negative: 12 (32)1 Gram Positive: 3 (8)2 Viral: 22 (58) Respiratory viruses: 15 (39)3 Reactivated viruses: 7 (18)4 AFB: 1 (3)5 |
| Treatment and outcomes | |
|
Total antibiotic duration (days; median, IQR) IV PO |
5 (3–9) 3 (3–4) 5 (5–10) |
| Hospital admission (n, %) | 63 (57) |
| Outcome at 30 days (n, %) |
Survival: 108 (97) Death: 3 (3)6 |
!MDI microbiologically diagnosed infection, CDI clinically diagnosed infection, FUF fever of unknown focus.
aThere were 2 pathogens isolated in 5 infective episodes: adenovirus & EBV, Haemophilus influenza & rhinovirus, influenza & adenovirus, S. aureus & E. coli, Bordetella parapertussis & rhinovirus/enterovirus.
1Salmonella sp. (n = 3), Bordetella parapertussis (n = 1), Escherichia coli (n = 3), Pseudomonas aeruginosa (n = 1), Haemophilus influenzae (n = 2), Klebsiella pneumoniae (n = 1), Proteus mirabilis (n = 1).
2Clostridium difficile (n = 1), Enterococcus faecalis (n = 1), Staphylococcus aureus (n = 1).
3Rhinovirus/enterovirus (n = 8), influenza (n = 1), adenovirus (n = 4), COVID-19 (n = 2).
4BK virus (n = 1), cytomegalovirus (n = 4), herpes simplex virus 2 (n = 1), Epstein Barr virus (n = 1).
5Mycobacterium avium complex (n = 1).
6Deaths attributed to preceding infection within 30 days.